DE69328722D1 - Adenosinderivate mit a2 agonistwirkung - Google Patents

Adenosinderivate mit a2 agonistwirkung

Info

Publication number
DE69328722D1
DE69328722D1 DE69328722T DE69328722T DE69328722D1 DE 69328722 D1 DE69328722 D1 DE 69328722D1 DE 69328722 T DE69328722 T DE 69328722T DE 69328722 T DE69328722 T DE 69328722T DE 69328722 D1 DE69328722 D1 DE 69328722D1
Authority
DE
Germany
Prior art keywords
hydrogen
alkyl
pct
cycloalkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69328722T
Other languages
English (en)
Other versions
DE69328722T2 (de
Inventor
Gloria Cristalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69328722D1 publication Critical patent/DE69328722D1/de
Application granted granted Critical
Publication of DE69328722T2 publication Critical patent/DE69328722T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69328722T 1992-04-24 1993-04-21 Adenosinderivate mit a2 agonistwirkung Expired - Fee Related DE69328722T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI920973A IT1254915B (it) 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista
PCT/EP1993/000972 WO1993022328A1 (en) 1992-04-24 1993-04-21 Adenosine derivatives having a2 agonist activity

Publications (2)

Publication Number Publication Date
DE69328722D1 true DE69328722D1 (de) 2000-06-29
DE69328722T2 DE69328722T2 (de) 2000-12-14

Family

ID=11363039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328722T Expired - Fee Related DE69328722T2 (de) 1992-04-24 1993-04-21 Adenosinderivate mit a2 agonistwirkung

Country Status (9)

Country Link
US (1) US5593975A (de)
EP (1) EP0637315B1 (de)
JP (1) JPH07508718A (de)
AT (1) ATE193299T1 (de)
CA (1) CA2134067A1 (de)
DE (1) DE69328722T2 (de)
ES (1) ES2145774T3 (de)
IT (1) IT1254915B (de)
WO (1) WO1993022328A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
KR100668006B1 (ko) * 1999-02-01 2007-01-15 유니버시티 오브 버지니아 페이턴트 파운데이션 염증 반응을 치료하기 위한 조성물
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
AU2001278708A1 (en) * 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
AP2003002828A0 (en) * 2001-01-16 2003-09-30 Vascular Therapies Llc Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts.
JP4514452B2 (ja) * 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
CN1671399A (zh) * 2002-07-29 2005-09-21 Cv医药有限公司 利用a2a受体激动剂的心肌灌注显像
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050033044A1 (en) * 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
AU2004285013A1 (en) * 2003-10-31 2005-05-12 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
WO2006015357A2 (en) 2004-08-02 2006-02-09 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
AU2005295437B2 (en) * 2004-10-20 2011-05-19 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
PT1989214T (pt) 2006-02-03 2016-09-22 Gilead Sciences Inc Processo para preparar um agonista de recetor de adenosina a2a e polimorfos do mesmo
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
ES2384337T3 (es) 2006-04-21 2012-07-03 Novartis Ag Derivados de purina para su uso como agonistas del receptor de adenosina A2A
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP1903044A1 (de) 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
WO2008042796A2 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
EP2344145A1 (de) * 2008-09-29 2011-07-20 Gilead Sciences, Inc. Kombinationen eines ratenkontrollierenden mittels und eines a-2-alpha-rezeptor-antagonisten zur verwendung in multidetektor-computertomographie-verfahren
CA2766073A1 (en) 2009-06-30 2011-01-06 Forest Laboratories Holdings Limited Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2ar agonists
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
CN104582709A (zh) 2012-08-01 2015-04-29 路易斯与克拉克药品公司 作为a2a激动剂的n-烷基2-(双取代的)炔基腺苷-5’-糖醛酰胺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
EP0267878A1 (de) * 1986-11-14 1988-05-18 Ciba-Geigy Ag N9-Cyclopentylsubstituierte Adeninderivate
EP0277917A3 (de) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Bestimmte Derivate von Adenosin-5'-carboxamid
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents

Also Published As

Publication number Publication date
EP0637315A1 (de) 1995-02-08
ITMI920973A1 (it) 1993-10-24
US5593975A (en) 1997-01-14
EP0637315B1 (de) 2000-05-24
ES2145774T3 (es) 2000-07-16
IT1254915B (it) 1995-10-11
CA2134067A1 (en) 1993-11-11
WO1993022328A1 (en) 1993-11-11
ITMI920973A0 (it) 1992-04-24
JPH07508718A (ja) 1995-09-28
DE69328722T2 (de) 2000-12-14
ATE193299T1 (de) 2000-06-15

Similar Documents

Publication Publication Date Title
DE69328722T2 (de) Adenosinderivate mit a2 agonistwirkung
DE69105131D1 (de) 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE194839T1 (de) Pyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
DE69324479T2 (de) Hypolipidämische benzothiazepin verbindungen
BR8807101A (pt) Compostos heterociclicos
DE69332718D1 (de) Enantiomere von carbazolderivaten als 5-ht1-ähnliche agonisten
ATE196293T1 (de) Triazole enthaltende antifungizide mittel
MX9304467A (es) Nuevos derivados fosfonados de ariletanolaminas, procedimiento para su preparacion y composiciones farmaceuticas y veterinarias que los contienen.
ATE168105T1 (de) Melamine derivate zur verwendung in der behandlung von krebs
ES2115053T3 (es) Derivados indolicos inhibidores de la 5alfa-reductasa de esteroides.
ATE182891T1 (de) Indazolderivate
HUP0101469A2 (hu) 5-[(2-Imidazolidinilidén)-amino]-benzimidazol-származékok, előállításuk és alkalmazásuk javított metabolikus stabilitású alfa-adrenoceptor agonistákként
MX9203100A (es) Nuevos peptidos, su preparacion y su aplicacion.
DE59209175D1 (de) Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln
MX9203939A (es) Derivados de hidroisoquinolina y composiciones farmaceuticas que los contienen.
KR960706476A (ko) 인터류킨-1 활성 억제제로서의 신규한 벤젠설포닐아민 유도체(Novel benzen-esulfonylimine derivatives as inhibitors of lL-1 action)
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
BR9801448B1 (pt) compostos heterocÍclicos, processo para sua preparaÇço e composiÇÕes farmacÊuticas contendo os mesmos.
AU1027188A (en) Sweetening agents derived from guanidinoacetic and ethanamidinoacetic acids, process for sweetening various products, and compositions containing such sweetening agents
DK0623118T3 (da) Carbamatderivater og deres anvendelse i medicin
ATE99326T1 (de) N-phenyl-n-alkoxycarbonylalkyl-glycinamide, ihre herstellung und sie enthaltende medikamente.
NZ238644A (en) 2-(1-oxo-alkoxy)alkanoic acid derivatives and pharmaceutical compositions thereof
TW333525B (en) New perhydroisoindole derivatives, their preparation and the pharmaceutical compositions which contain them the invention relates to perhydroisoindole derivatives of general formula (I), and their salts when they exist advantageously as neurokinin A antagonists.
HU9401963D0 (en) Isoxazole carboxylic acid amides, process for producing them and their use

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee